What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
Internal medicine, Glioma, Cancer research, Oncology and Surgery are his primary areas of study.
His Internal medicine and Clinical trial, Phases of clinical research, Temozolomide, Survival rate and Randomized controlled trial investigations all form part of his Internal medicine research activities.
His Glioma study combines topics from a wide range of disciplines, such as Proliferation index, Progression-free survival, Antigen-presenting cell and Brain tumor, Pathology.
The concepts of his Cancer research study are interwoven with issues in Cancer, Epidermal growth factor receptor, Protein kinase B, Immunology and PTEN.
His Oncology research is multidisciplinary, incorporating elements of Central nervous system disease, Radiation therapy, Toxicity and Chemotherapy.
His work in Surgery addresses subjects such as Hazard ratio, which are connected to disciplines such as Proportional hazards model.
His most cited work include:
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group (2349 citations)
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma (1837 citations)
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma (1454 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Internal medicine, Oncology, Glioma, Cancer research and Bevacizumab.
He interconnects Surgery and Glioblastoma in the investigation of issues within Internal medicine.
His Oncology research integrates issues from Clinical trial, Proportional hazards model and Chemotherapy.
His research integrates issues of Cancer, Mutant, IDH1, Pathology and Magnetic resonance imaging in his study of Glioma.
His work deals with themes such as PI3K/AKT/mTOR pathway, Protein kinase B, Signal transduction, Epidermal growth factor receptor and Immunology, which intersect with Cancer research.
As part of the same scientific family, Timothy F. Cloughesy usually focuses on Bevacizumab, concentrating on Nuclear medicine and intersecting with Effective diffusion coefficient.
He most often published in these fields:
- Internal medicine (38.06%)
- Oncology (32.39%)
- Glioma (26.72%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (38.06%)
- Glioma (26.72%)
- Oncology (32.39%)
In recent papers he was focusing on the following fields of study:
Timothy F. Cloughesy mainly focuses on Internal medicine, Glioma, Oncology, Cancer research and Glioblastoma.
Internal medicine is a component of his Bevacizumab, Phases of clinical research, Temozolomide, Recurrent glioblastoma and Clinical trial studies.
His Glioma study integrates concerns from other disciplines, such as Pharmacokinetics, Mutant, Immune system, Magnetic resonance imaging and Proportional hazards model.
As a part of the same scientific study, Timothy F. Cloughesy usually deals with the Oncology, concentrating on Adverse effect and frequently concerns with Gastroenterology.
His Cancer research study combines topics in areas such as Phenotype, Cancer, DNA methylation and In vivo.
His biological study spans a wide range of topics, including Brain tumor, Combined Modality Therapy and Medical physics.
Between 2017 and 2021, his most popular works were:
- Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. (309 citations)
- Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143 (159 citations)
- First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. (146 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
The scientist’s investigation covers issues in Internal medicine, Oncology, Glioma, Glioblastoma and Clinical trial.
His research brings together the fields of Gastroenterology and Internal medicine.
His Oncology research includes themes of Survival rate, Biomarker, Magnetic resonance imaging and Radiation therapy.
Glioma is a subfield of Cancer research that Timothy F. Cloughesy investigates.
His study looks at the intersection of Glioblastoma and topics like Newly diagnosed with Dendritic cell vaccine and Placebo.
His Clinical trial research incorporates elements of O-6-methylguanine-DNA methyltransferase and MEDLINE.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
